Table 2.
Characteristics of melanoma patients and normal subject controls of the independent internal validation cohort
| Melanoma patients (N=20) | Normal control (N=18) | |
|---|---|---|
| Gender | ||
| Male | 13(65%)a | 11 (61,1%)a |
| Female | 7 (35%)a | 7 (38,9%)a |
| Age (range) | ||
| Male | 58(43-79)b | 58 (41-67)b |
| Female | 48 (20-67)b | 53 (21-65)b |
| BRAF status | ||
| Mutated | 8 (40%)a | – |
| Wild-type | 8 (40%)a | |
| Unknown | 4 (20%)a | |
| M stage | ||
| M1c | 20 (100%)a | |
| Number of brain lesions | ||
| 1 | 7 (35%)a | – |
| 2 | 5 (25%)a | |
| 3 | 5 (25%)a | |
| >3 | 3 (15%)a | |
| Previous local treatments for brain metastases | ||
| Surgery | 5 (25%)a | – |
| Radiotherapy | 2 (10%)a | |
| LDH | – | |
| ≤ULN | 15 (75%)a | |
| >ULN | 5 (25%)a | |
LDH lactate dehydrogenase, UNL upper limit normal
a n (%)
b Median (range).